ChemicalBook > CAS DataBase List > Nimotuzumab

Nimotuzumab

Product Name
Nimotuzumab
CAS No.
780758-10-3
Chemical Name
Nimotuzumab
Synonyms
Nimotuzumab (anti-EGFR)
CBNumber
CB54845998
Formula Weight
0
MOL File
Mol file
More
Less

Nimotuzumab Property

storage temp. 
Store at -20°C
form 
Liquid
color 
Colorless to light yellow
More
Less

Hazard and Precautionary Statements (GHS)

More
Less

N-Bromosuccinimide Price

American Custom Chemicals Corporation
Product number
ATB0009396
Product name
NIMOTUZUMAB
Purity
95.00%
Packaging
5MG
Price
$504.11
Updated
2021/12/16
More
Less

Nimotuzumab Chemical Properties,Usage,Production

Description

Nimotuzumab(Taixinsheng) is a biologically targeted drug that acts on the epidermal growth factor receptor (EGFR) on the surface of tumor cells, inhibiting the proliferation and differentiation of tumor cells. It has the advantages of low reaction and good safety.
Suitable for head and neck tumors, gliomas, colorectal cancer, pancreatic cancer, esophageal cancer, liver cancer, non-small cell lung cancer and other solid tumors.

Uses

Nimotuzumab is a humanized IgG1 monoclonal antibody targeting EGFR with a KD of 0.21 nM. Nimotuzumab is directed against the extracellular domain of the EGFR blocking the binding to its ligands. Nimotuzumab, a strong antitumor agent, is cytolytic on target tumors by its capacity to cause antibody dependent cell mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC)[1][2].

Pharmacology

Nimotuzumab, as the first humanized monoclonal antibody in my country, can competitively bind to EGFR and block its conduction pathway, thereby inhibiting tumor cell proliferation and tumor angiogenesis, thereby enhancing the efficacy of radiotherapy and chemotherapy.

target

EGFR

References

[1] Zaima Mazorra, et al. Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer Patients. Front Pharmacol. 2017 Jun 19;8:382. DOI:10.3389/fphar.2017.00382
[2] Melarkode S Ramakrishnan, et al. Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin. MAbs. Jan-Feb 2009;1(1):41-8. DOI:10.4161/mabs.1.1.7509

Nimotuzumab Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

Nimotuzumab Suppliers

Shanghai EFE Biological Technology Co., Ltd.
Tel
021-65675885 18964387627
Fax
021-65675885
Email
info@efebio.com
Country
China
ProdList
9803
Advantage
58
Shanghai YuanYe Biotechnology Co., Ltd.
Tel
021-61312847; 18021002903
Fax
QQ:3008007432
Email
3008007409@qq.com
Country
China
ProdList
71826
Advantage
60
Wuhan Topule
Tel
+86-02787215551 +86-19945035818
Fax
027-87215551
Email
2936752263@qq.com
Country
China
ProdList
7986
Advantage
58
cjbscvictory
Tel
13348960310
Email
3003867561@qq.com
Country
China
ProdList
10503
Advantage
58
Hubei Kele Fine Chemical Co., Ltd
Tel
027-59101668 19945030958
Fax
027-59101668
Email
2881924765@qq.com
Country
China
ProdList
7938
Advantage
58
Wuhan Augda Biotechnology Co., Ltd
Tel
15071299552
Fax
QQ:262933239
Email
262933239@qq.com
Country
China
ProdList
7048
Advantage
58
Wuhan Jingkangen Biomedical Technology Co., Ltd
Tel
13720134139 086-15871494362 13720134139
Email
orders@jknbiochem.com
Country
China
ProdList
6762
Advantage
58
Shanghai jerryxing Biomedical Technology Co., Ltd
Tel
17721492509; 17721492509
Email
643638326@qq.com
Country
China
ProdList
4970
Advantage
58
Hubei wei shi reagent group ltd., company
Tel
027-59102966 18717199209
Email
2853877583@QQ.com
Country
China
ProdList
7498
Advantage
58
Olix (Shanghai) Pharmaceutical Technology Co., Ltd
Tel
17316404525 17316404525
Email
209533805@qq.com
Country
China
ProdList
9766
Advantage
58

780758-10-3, NimotuzumabRelated Search:


  • Nimotuzumab (anti-EGFR)
  • 780758-10-3